Drug Survival in Biologic Therapy. Do We Know What it Means? Can We Calculate it?

Drug survival in biologic therapy. Do we know what it means? Can we calculate it?

Now that biologic therapy has been used for some years in the treatment of psoriasis and we anticipate short and medium term outcomes consistent with the results of the pivotal clinical trials, the objective of the dermatologist with experience in managing this condition has changed. We now look beyond the predicted response to weigh up the likelihood that a given drug which achieves a satisfac...

What Do We Know, How Do We Know It, and How Can We Best Apply It?

Adequate Nutrition May get You Home: Effect of Caloric/Protein Deficits on the Discharge Destination of Critically Ill Surgical Patients 37 D. Dante Yeh, MD; Eva Fuentes, MD; Sadeq A. Quraishi, MD, MHA, MMScH; Catrina Cropano, MSc; Haytham Kaafarani, MD, MPH; Jarone Lee, MD, MPH; David R. King, MD; Marc DeMoya, MD; Peter Fagenholz, MD; Kathryn Butler, MD; Yuchiao Chang, PhD; and George Velmahos...

What do we know and when do we know it?

Two essential aspects of virtual screening are considered: experimental design and performance metrics. In the design of any retrospective virtual screen, choices have to be made as to the purpose of the exercise. Is the goal to compare methods? Is the interest in a particular type of target or all targets? Are we simulating a 'real-world' setting, or teasing out distinguishing features of a me...

Superior Capsule Reconstruction: What Do We Know?

The management of irreparable rotator cuff tears remains challenging. Since its introduction by Mihata in 2012, superiorcapsule reconstruction (SCR) has grown in popularity at an astonishingly rapid rate. The aim of this article is to providea comprehensive review of the available literature, in order to highlight what has so far been published on SCR,covering all aspects including biomechanica...

Do We Know What We Do not Know? A Response to Celine Bonnet